January 08, 2026 a 09:00 pm
LLY: Analysts Ratings - Eli Lilly and Company
Eli Lilly and Company, renowned for its innovative pharmaceuticals, particularly in diabetes and oncology, has been maintaining a stable footing in the market. With consistent analyst ratings largely favoring 'Buy' and 'Strong Buy', it remains a promising candidate for investors. However, recent shifts in analyst opinions suggest a cautious approach may be emerging.
Historical Stock Grades
Here's a detailed look at the latest available analyst ratings for Eli Lilly and Company as of January 2026, showing a continued strength in 'Buy' recommendations with minimal 'Sell' indications.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 18 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
- Over the past year, a slight downtrend in 'Strong Buy' ratings is observable. Initially stable, the sentiment now reflects cautious optimism.
- The 'Buy' category maintains its strength, consistently representing a majority of the recommendations, thereby emphasizing confidence in the company's performance.
- There's been a gradual uptick in 'Hold' recommendations from mid-2025, suggesting a balanced approach by analysts amid market fluctuations.
Percentage Trends
The distribution of analyst ratings reveals potential mood shifts, emphasizing a slight retreat from stronger endorsements toward more moderate ('Hold') recommendations.
- From June 2025 to December 2025, the percentage of 'Strong Buy' ratings declined from 21% to 14%.
- 'Buy' ratings have remained relatively stable, underscoring a steady positive outlook.
- 'Hold' recommendations have increased in proportion, from 16% in June 2025 to 25% in January 2026, marking growing prudence among analysts.
Latest Analyst Recommendations
Below are the most recent recommendations, showing stability with no significant shifts in the short term.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-15 | Buy | Buy | B of A Securities |
| 2025-12-10 | Overweight | Overweight | Wells Fargo |
| 2025-12-04 | Outperform | Outperform | BMO Capital |
| 2025-12-03 | Buy | Buy | Guggenheim |
| 2025-11-24 | Overweight | Overweight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Recent changes in analyst opinions indicate subtle repositioning, which may hint at varying market perspectives.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-10 | Hold | Buy | Freedom Capital Markets |
| 2025-11-10 | Outperform | Market Perform | Leerink Partners |
| 2025-09-17 | Hold | Buy | Berenberg |
| 2025-08-27 | Hold | Reduce | HSBC |
| 2025-04-28 | Reduce | Buy | HSBC |
Interpretation
The data suggests a mixed but generally positive sentiment towards Eli Lilly's stock. The stability in 'Buy' ratings alongside increased 'Hold' indicates a cautious but optimistic market sentiment. Although some downgrades suggest uncertainties, the lack of significant 'Sell' recommendations reflects overall confidence in the company's prospects.
Conclusion
In conclusion, Eli Lilly and Company exhibits a stable growth trajectory, primarily supported by robust 'Buy' ratings. The shift towards more 'Hold' recommendations mirrors market caution, potentially reflecting broader economic factors or internal company developments. For investors, Eli Lilly remains an attractive option, balanced by the moderate cautious stance observed in recent analyst shifts. This equilibrium presents both opportunities and risks, highlighting the importance of ongoing market and internal company performance evaluations.